SELLAS Life Sciences Group, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>SELLAS Life Sciences Group, Inc. filed its 2023 10-K, detailing its business operations and subsequent financing activities.</b>

AI Summary

SELLAS Life Sciences Group, Inc. (SLS) filed a Annual Report (10-K) with the SEC on March 28, 2024. The company filed its 2023 Form 10-K on March 28, 2024, reporting on the fiscal year ending December 31, 2023. SELLAS Life Sciences Group, Inc. was formerly known as Galena Biopharma, Inc. and RXi Pharmaceuticals Corp. The company's principal executive offices are located at 7 Times Square, Suite 2503, New York, NY 10036. Key events in the subsequent period include a March 2024 Registered Direct Offering and a January 2024 Public Offering. A Registered Direct Offering involving pre-funded warrants occurred on November 2, 2023.

Why It Matters

For investors and stakeholders tracking SELLAS Life Sciences Group, Inc., this filing contains several important signals. The 10-K filing provides a comprehensive overview of the company's financial health, operational status, and strategic initiatives for the fiscal year 2023. Subsequent events disclosed in the filing highlight recent financing activities, including registered direct offerings and public offerings, which are crucial for funding ongoing research and development.

Risk Assessment

Risk Level: medium — SELLAS Life Sciences Group, Inc. shows moderate risk based on this filing. The company's financial disclosures are limited in this header, and a full analysis of its financial health, including revenue, net income, and debt, requires a deeper dive into the full 10-K document.

Analyst Insight

Review the full 10-K filing to analyze SELLAS Life Sciences Group's financial performance, R&D pipeline, and the impact of recent financing events on its future prospects.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-28 — Filing Date (Filed as of date)
• 2024-03-19 — March 2024 Registered Direct Offering (Subsequent event)
• 2024-01-08 — January 2024 Public Offering (Subsequent event)
• 2023-11-02 — November 2023 Registered Direct Offering (Subsequent event)

Key Players & Entities

• SELLAS Life Sciences Group, Inc. (company) — Filer name
• Galena Biopharma, Inc. (company) — Former company name
• RXi Pharmaceuticals Corp (company) — Former company name
• 7 Times Square, Suite 2503, New York, NY 10036 (company) — Business address

FAQ

Industry Context

SELLAS Life Sciences Group operates in the pharmaceutical preparations industry, focusing on the development and commercialization of novel cancer immunotherapies.

Regulatory Implications

As a publicly traded company, SELLAS Life Sciences Group is subject to the regulations of the Securities and Exchange Commission (SEC), requiring regular filings like the 10-K.

What Investors Should Do

1. Analyze the full 10-K for detailed financial statements, including revenue, expenses, and cash flow.
2. Investigate the company's product pipeline and clinical trial progress for key drug candidates.
3. Assess the impact of the recent registered direct and public offerings on the company's capital structure and liquidity.

Key Dates

• 2023-12-31: Fiscal Year End — Reporting period for the 10-K
• 2024-03-28: 10-K Filing Date — Official filing date of the annual report
• 2024-03-19: March 2024 Registered Direct Offering — Significant subsequent financing event
• 2024-01-08: January 2024 Public Offering — Significant subsequent financing event

Year-Over-Year Comparison

This filing is the 2023 Form 10-K, providing an update on the company's financial and operational status compared to previous periods.

Key Financial Figures

• $0.0001 — ange on Which Registered Common Stock, $0.0001 Par Value per share SLS The Nasdaq Stoc
• $10.5 million — 2024, we have received an aggregate of $10.5 million in upfront and milestone payments under
• $191.5 million — 3D Medicines Agreement, and a total of $191.5 million in potential future development, regula

Filing Documents

• sls-20231231.htm (10-K) — 1891KB
• sls-20231231ex1049.htm (EX-10.49) — 22KB
• sls-20231231ex1050.htm (EX-10.50) — 91KB
• sls-20231231ex1051.htm (EX-10.51) — 98KB
• sls20231231ex211nextgen.htm (EX-21.1) — 5KB
• sls20231231ex231nextgen.htm (EX-23.1) — 2KB
• sls20231231ex311nextgen.htm (EX-31.1) — 8KB
• sls20231231ex312nextgen.htm (EX-31.2) — 8KB
• sls20231231ex321nextgen.htm (EX-32.1) — 9KB
• sls20231231ex97.htm (EX-97) — 25KB
• image_0a.jpg (GRAPHIC) — 181KB
• sls-20231231_g1.jpg (GRAPHIC) — 30KB
• sls-20231231_g2.jpg (GRAPHIC) — 67KB
• sls-20231231_g3.jpg (GRAPHIC) — 22KB
• sls-20231231_g4.jpg (GRAPHIC) — 254KB
• sls-20231231_g5.jpg (GRAPHIC) — 31KB
• sls-20231231_g6.jpg (GRAPHIC) — 52KB
• sls-20231231_g7.jpg (GRAPHIC) — 70KB
• sls-20231231_g8.jpg (GRAPHIC) — 69KB
• sls-20231231_g9.jpg (GRAPHIC) — 652KB
• 0001390478-24-000004.txt (&nbsp;) — 10876KB
• sls-20231231.xsd (EX-101.SCH) — 52KB
• sls-20231231_cal.xml (EX-101.CAL) — 65KB
• sls-20231231_def.xml (EX-101.DEF) — 170KB
• sls-20231231_lab.xml (EX-101.LAB) — 605KB
• sls-20231231_pre.xml (EX-101.PRE) — 406KB
• sls-20231231_htm.xml (XML) — 773KB

Risk Factors

Item 1A Risk Factors 59

Unresolved Staff Comments

Item 1B Unresolved Staff Comments 113

Cybersecurity

Item 1C Cybersecurity 113

Properties

Item 2 Properties 114

Legal Proceedings

Item 3 Legal Proceedings 114

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 115 PART II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 116

[Reserved]

Item 6 [Reserved] 117

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations 118

Quantitative and Qualitative Disclosures about Market Risk

Item 7A Quantitative and Qualitative Disclosures about Market Risk 131

Financial Statements and Supplementary Data

Item 8 Financial Statements and Supplementary Data 132

Change in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9 Change in and Disagreements with Accountants on Accounting and Financial Disclosure 158

Controls and Procedures

Item 9A Controls and Procedures 158

Other Information

Item 9B Other Information 159

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 160 PART III

Directors, Executive Officers and Corporate Governance

Item 10 Directors, Executive Officers and Corporate Governance 161

Executive Compensation

Item 11 Executive Compensation 161

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 161

Certain Relationships and Related Transactions, and Director Independence

Item 13 Certain Relationships and Related Transactions, and Director Independence 161

Principal Accounting Fees and Services

Item 14 Principal Accounting Fees and Services 161 PART IV

Exhibits

Item 15 Exhibits 162

Form 10-K Summary

Item 16 Form 10-K Summary 165

Signatures

Signatures 166 Unless the context otherwise indicates, references in these notes to the "Company," "we," "us" or "our" refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. The names "SELLAS Life Sciences Group, Inc.," "SELLAS," the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Annual Report on Form 10-K are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this prospectus are the property of their respective owners. We do not intend the use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either, of these other companies. Table of Contents SUMMARY OF PRINCIPAL RISK FACTORS This summary briefly lists the principal risks and uncertainties facing our business, which are only a select portion of those risks. A more complete discussion of those risks and uncertainties is set forth in Part I, Item 1A of this Annual Report on Form 10-K, entitled "Risk Factors." Additional risks not presently known to us or that we currently deem immaterial may also affect us. If any of these risks occur, our business, financial condition or results of operations could be materially and adversely affected. Our business is subject to the following principal risks and uncertainties: We have incurred substantial losses since our inception and anticipate that we will continue to incur substantial and increasing losses for the foreseeable future as we continue development and, subject to positive data and regulatory approval, the commercialization of our product candidates. We currently have no source of product revenues. We may never generate such revenues or achieve profitability. We will need additional financing to fund our operations and complete the development and, subject to positive data and regulatory approval, the commercialization of our p

BUSINESS

ITEM 1. BUSINESS Overview We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (formerly, GFH009), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. Galinpepimut-S Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the WT1 protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers, and solid tumor indications. In January 2020, we commenced in the United States an open label randomized Phase 3 clinical trial, the REGAL study, for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of second complete remission, or CR2, following successful completion of second-line antileukemic therapy. Patients are randomized to receive either GPS or best available treatment, or BAT. We expect this study will be used as the basis for submission of a Biologics License Application, or BLA, subject to a statistically significant and clinically meaningful data outcome and agreement with the U.S. Food and Drug Administration, or the FDA. The primary endpoint of the REGAL study is overall survival, or OS. We planned to enroll approximately 125 to 140 patients at approximately 95 clinical sites in North America, Europe and Asia with a planned interim safety, efficacy and futility analysis after 60 events (deaths). In March 2024, we announced the completion of enrollment. Under our current assumptions with respect to enrollment and the estimated survival t

View Full Filing

View this 10-K filing on SEC EDGAR